Novartis Receives FDA Approval for Cosentyx in Non-Radiographic Axial Spondyloarthritis

Novartis today announced that the FDA has approved Cosentyx (secukinumab) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging. In the Phase 3 PREVENT trial, Cosentyx demonstrated a statistically significant improvement in the Assessment of SpondyloArthritis International Society 40 (ASAS40) response rate compared to placebo. This approval expands Cosentyx's use into nr-axSpA, adding to its existing approvals in ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.